About: A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 06 December 2011

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в грудні 2011 (uk) article scientifique publié en 2011 (fr) im Dezember 2011 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu n'avientu de 2011 (ast) scientific article published on 06 December 2011 (en)
publication date	wds:Q82837990-BB2DEEED-9C58-4171-A2B7-181D6062E056
publication date	2011-12-06 00:00:00Z (xsd:dateTime)
author name string	wds:Q82837990-043F90FF-04C2-4679-AA46-4E85FAB1A896 wds:Q82837990-2507BE16-24F5-4FD6-BBC0-96FDAD6BEF80 wds:Q82837990-3DF9380D-F83F-4A4C-BB41-D24A97D8282A wds:Q82837990-57AD0D16-0D70-4040-9E63-377941AB15DE wds:Q82837990-5D7D833B-E4F1-4D94-883B-C69EA76A308F wds:Q82837990-6A8202DF-0FA2-4E53-9C2D-EC2AE31A1446 wds:Q82837990-819FCB72-6B27-4C50-B1C4-9AF981C39505 wds:Q82837990-96F43EF5-A868-4C06-9A47-5818E8B3369D wds:Q82837990-D66AECE8-8166-4261-AD84-DA3727AC4480 wds:Q82837990-DF302205-5312-436B-AFFF-457030F78D5C wds:Q82837990-FAA6662F-0F0C-4C26-BC4C-A6B8EE0FF5F7
author name string	Heidi Leblanc Geoff Nichol Allison Luo Li-An Xu Michael Yellin Xiaolu Tao Andra Balanescu Pina M Cardarelli Rodica Chirieac Semen Ter-Vartanian Vira Tseluyko
rdfs:label	A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis (en) A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis (nl)
skos:prefLabel	A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis (en) A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis (nl)
name	A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis (en) A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis (nl)
author	wds:Q82837990-4A8A579B-8DFD-452E-B52C-76DC285D10EC wds:Q82837990-B056E00C-258B-42DB-A96F-98456EEBC582
author	Codrina Ancuta Igor Paliienko
title	wds:Q82837990-923C28E4-49C2-431A-9D7D-72663B059577
title	A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis (en)
page(s)	wds:Q82837990-D45588E9-6B9A-44D1-9D09-3DA1D73FC7B7
page(s)	1730-1739
instance of	wds:Q82837990-8D296EF5-0ED6-46CD-B989-5A1310264996
instance of	scholarly article
main subject	wds:Q82837990-3026C7B0-413E-4DAD-9F29-983F4E98A725 wds:Q82837990-55D87C67-D368-4C9F-BDDC-7749AD879D99 wds:Q82837990-D819CE1A-AACC-4DA4-8F24-F2C3A083EA5F wds:Q82837990-DFB17316-60A6-473C-9882-CE2DB2575F57
main subject	rheumatoid arthritis placebo wd:Q422232 monoclonal antibody
PubMed ID	wds:Q82837990-9778664D-F9F3-4523-959B-6F6FC37A650A
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/22147649
PubMed ID	22147649
published in	wds:Q82837990-A070A008-B0A1-425F-8214-5DFB81606882
published in	Arthritis and Rheumatism
issue	wds:Q82837990-3EA5A778-ECBD-4B77-928F-0D2D78C061D6
volume	wds:Q82837990-1A71163F-9365-4FBC-B53F-787D8CC99843
issue	6
volume	64
DOI	wds:Q82837990-D928BCD3-FE0D-4369-9429-5459C0B486EE
DOI	http://dx.doi.org/10.1002/ART.34330
DOI	10.1002/ART.34330
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q82837990
is cites work of	Prolonged tumor necrosis factor α primes fibroblast-like synoviocytes in a gene-specific manner by altering chromatin. International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors Monoclonal antibody against CXCL-10/IP-10 ameliorates influenza A (H1N1) virus induced acute lung injury Transitioning from Idiopathic to Explainable Autoimmune Hepatitis CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis IL-10 downregulates CXCR3 expression on Th1 cells and interferes with their migration to intestinal inflammatory sites Successes and failures of chemokine-pathway targeting in rheumatoid arthritis Chemokines: established and novel targets in atherosclerosis Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study B cells as therapeutic targets in SLE. Liver X receptor regulates rheumatoid arthritis fibroblast-like synoviocyte invasiveness, matrix metalloproteinase 2 activation, interleukin-6 and CXCL10. Chemokines and chemokine receptors: update on utility and challenges for the clinician Primed Mycobacterial Uveitis (PMU): Histologic and Cytokine Characterization of a Model of Uveitis in Rats The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis CXCR3 Blockade Inhibits T Cell Migration into the Skin and Prevents Development of Alopecia Areata Trial Watch: Immunostimulatory cytokines CXCL13 antibody for the treatment of autoimmune disorders Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expression The cation channel Trpv2 is a new suppressor of arthritis severity, joint damage, and synovial fibroblast invasion Current stage in inflammatory bowel disease: What is next? CXCL9 and CXCL10 gene polymorphisms in patients with rheumatoid arthritis Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies Chemokine receptors as important regulators of pathogenesis during arboviral encephalitis Therapeutic effect of anti-C-X-C motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse. Loss of menin in osteoblast lineage affects osteocyte-osteoclast crosstalk causing osteoporosis Pathogenic roles of CXCL10 signaling through CXCR3 and TLR4 in macrophages and T cells: relevance for arthritis. Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker. Comparative efficacy and tolerability of treatments for adult autoimmune hepatitis: A systematic review and network meta-analysis. Upregulation of chemokine CXCL10 enhances chronic pulmonary inflammation in tree shrew collagen-induced arthritis. An initial investigation into endothelial CC chemokine expression in the human rheumatoid synovium.

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 180 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software